Your browser doesn't support javascript.
loading
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Schmieder, Roberta; Puehler, Florian; Neuhaus, Roland; Kissel, Maria; Adjei, Alex A; Miner, Jeffrey N; Mumberg, Dominik; Ziegelbauer, Karl; Scholz, Arne.
Affiliation
  • Schmieder R; Global Drug Discovery, Bayer HealthCare, Berlin, Germany.
Neoplasia ; 15(10): 1161-71, 2013 Oct.
Article in En | MEDLINE | ID: mdl-24204195
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylurea Compounds / Sulfonamides / Niacinamide / Carcinoma, Hepatocellular / Mitogen-Activated Protein Kinase 1 / Mitogen-Activated Protein Kinase 3 / Diphenylamine / Liver Neoplasms / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Journal: Neoplasia Journal subject: NEOPLASIAS Year: 2013 Document type: Article Affiliation country: Alemania
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylurea Compounds / Sulfonamides / Niacinamide / Carcinoma, Hepatocellular / Mitogen-Activated Protein Kinase 1 / Mitogen-Activated Protein Kinase 3 / Diphenylamine / Liver Neoplasms / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Journal: Neoplasia Journal subject: NEOPLASIAS Year: 2013 Document type: Article Affiliation country: Alemania